China believes that vaccine disorders can boost low effectiveness
The Chinese Disease Control Center is thinking about mixing vaccines and changing the sequence of doses to improve effectiveness. This is the first time a government agency has publicly discussed that there are problems with the effectiveness of Chinese owners.
CDC chief Gao Fu said at a forum on Saturday that the agency was “looking at how to solve the problem that the effectiveness of existing vaccines is not high,” according to local media.
In a post on Weibo’s social media that is no longer available, he said Gao’s comments on the influential “Vaccines and Science” account were “very honest”. But he reminded readers that taking ownership was still important to protect the country. He added, “We can’t wait for the vaccine to be perfect before we get vaccinated.”
Gao proposed mixing different vaccines, as well as changing the sequence of doses, such as changing the number and quantity of doses and the interval between them.
Some of Weo’s social media posts about Gao’s remarks were quickly censored, according to Yanzhong Huang, a senior fellow in global health at the Foreign Relations Council.
“It’s the first time. . . a government official publicly acknowledged that the rate of protection is a concern to boost the vaccine, ”Huang added.
China delivered 65m doses across the country until mid-March.
Unlike other vaccine producers, Chinese manufacturers have not published Phase 3 trials, and have complained about the lack of transparency about their effects in different groups.
A new strategy will reach consensus in China in more than 20 countries, most notably on bilateral “vaccine diplomacy” agreements. In March, China delivered 40m doses abroad.
Chile Covid is facing another wave of new variants, although the Chinese Sinovac vaccine has been successfully spread. The effectiveness of a jab was only 3 percent, compared to 56 percent with two shots. Experts, however, have not linked the recent wave to the vaccine’s effectiveness rate.
Vaccine producers in other countries have also conducted dose experiments. In the UK, Oxford / AstraZeneca researchers encountered the effectiveness of lowering the initial dose after a dosing error.
Gao also proposed mixing different vaccines. So far, the only jab approved for use in China are conventional “inactivated” vaccines created by Sinopharm, Sinovac and other domestic groups, similar to the Oxford / AstraZeneca mechanism.
Sinopharm-ek a 79 percent efficiency rate, similar to the rates that AstraZeneca has just achieved in U.S. trials. However, AstraZeneca dropped its rates while suffering criticism releasing incomplete data, neither Sinopharm nor any of its Chinese members have publicly analyzed Phase 3 data.
Sinovac Biotech’s CoronaVac vaccine has an 50.66 percent effectiveness rate among people between the ages of 18 and 60, according to documents released by a team of experts in Hong Kong.
However, data from Phases 1 and 2 published in CoronaVac’s Lancet showed that the shots were “safe and well tolerated”.
Gao also warned that the reopening of China’s borders to foreigners banned from entering the country since March last year poses a risk to older people who have not yet been vaccinated.
The time of calming down borders will affect who will take part in the Beijing Winter Olympics in February 2022.